The Addition of Bevacizumab to Standard Therapy with R-CHOP in Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Is Associated with an Increased Rate of Cardiac Adverse Events: Final Analysis of Safety and Efficacy Outcomes From the...

Konference: 2012 54th ASH Annual Meeting - účast ČR

Kategorie: Maligní lymfomy a leukémie

Téma: 624. Lymphoma - Therapy with Biologic Agents, excluding Pre-Clinical Models

Číslo abstraktu: 0058

Autoři: Prof. John Francis Seymour, MD, PhD, MBBS, FRACP; MD Michael Pfreundschuh; MD Bertrand Coiffier; Prof. MUDr. Marek Trněný, CSc.; Laurie H. Sehn; Eva Csinady

Datum přednesení příspěvku: 9. 12. 2012